<DOC>
	<DOCNO>NCT01702454</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity GSK Biologicals ' investigational vaccine GSK2321138A child previously participate study 115345 ( FLU D-QIV-004 PRI ) ( NCT01439360 ) .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Influenza Vaccine When Administered Children Who Previously Participated Study 115345</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /LAR ( ) comply requirement protocol . Children , male female receive 2dose vaccination study 115345 ( NCT01439360 ) . Written inform consent obtain parent ( ) /LAR ( ) subject . Subjects stable health determine medical history clinical examination enter study . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Since start study 115345 ( NCT01439360 ) , receipt seasonal influenza vaccine study vaccine study 115345 plan administration influenza vaccine study vaccine study . Administration vaccine foreseen study protocol within 4 week precede first dose study vaccine plan use Visit 2 . Laboratory confirm influenza infection outside 115345 ( NCT01439360 ) study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior enrolment study plan administration study period . Inhaled topical steroid allow . Administration immunoglobulins and/ blood product within 3 month precede first dose study vaccine plan administration study period . History reaction hypersensitivity likely exacerbate component vaccine . Any contraindication intramuscular injection . Acute disease and/or fever time enrollment : Fever define temperature ≥ 37.5°C route . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator . Any condition , opinion Investigator , prevents subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>17 Months</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK Biologicals quadrivalent influenza vaccine</keyword>
	<keyword>Influenza</keyword>
	<keyword>Children</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>